ROME Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
201 Brookline Ave Ste 1001, Boston, Mass...Phone Number
(617) 902-0026Website
www.rometx.comRevenue
$16.9 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome vast stretches of uncharted genetic material that have long been dismissed as junk DNA. With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.Explore more
ROME Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ROME Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if ROME Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at ROME Therapeutics
Funding: Get notified immidiatlly once ROME Therapeutics has new funding data
Product Launch: Get notified when ROME Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on ROME Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if ROME Therapeutics had a recent Job posting/layoffs
ROME Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if ROME Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined ROME Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to ROME Therapeutics
Compare insights from companies similar to ROME Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ROME Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ROME Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ROME Therapeutics.
ROME Therapeutics financials insights
Gather financial insights about ROME Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$50M
2023
Series B
$149M
ROME Therapeutics Tech Stack
A closer look at the technologies used by ROME Therapeutics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Lateral Move
Executive Move
New Hire
Executive Move
ROME Therapeutics News & Media
ROME Therapeutics Debuts First Preclinical Data of its LINE-1 Reverse Transcriptase (RT) Inhibitors in Neurodegenerative Diseases at 3rd Annual Dark Genome Symposium
ROME Therapeutics debuts first preclinical data of its LINE-1 RT inhibitors in neurodegenerative diseases at 3rd Annual Dark Genome Symposium in NYC.ROME Therapeutics to Present Data Supporting LINE-1 Reverse Transcriptase Inhibitors as a Novel Treatment for Autoimmune Diseases at ACR Convergence 2024
Inhibition of LINE-1 Reverse Transcriptase (RT) holds promise as the first non-immunosuppressant treatment approach for Type 1 interferon-driven diseases Inhibition of LINE-1 Reverse Transcriptase (RT) holds promise as the first non-immunosuppressant treatment approach for Type 1 interferon-driven diseasesROME Therapeutics, Enara Bio, Nucleome Therapeutics and NYU Langone Health to Host 3rd Annual Dark Genome Symposium
ROME Therapeutics, Enara Bio, Nucleome Therapeutics and NYU Langone Health will host the 3rd Annual Dark Genome Symposium on Nov. 21 - 22 in New York, NY.ROME Therapeutics to Participate in 2024 Cantor Global Healthcare Conference
BOSTON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced that Rosana Kapeller, M.D., Ph.D., President, CEO and Co-Founder of ROME, and members of the company’s Senior Leadership Team, will participate in the Cantor Global Healthcare Conference on Wednesday, September 18, 2024 in New York, NY.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ROME Therapeutics
Sign Up For FreeTo access detailed company insights
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome vast stretches of uncharted genetic material that have long been dismissed as junk DNA. With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in bio... Read More
